Recent News

• 03.31.2026 - Co-Diagnostics Reports Full Year 2025 Financial Results
• 03.25.2026 - Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
• 03.20.2026 - Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
• 03.17.2026 - Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
• 03.16.2026 - Co-Diagnostics to Present at Medical Korea 2026
• 03.12.2026 - Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
• 03.10.2026 - Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements
• 02.09.2026 - Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
• 02.05.2026 - Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
• 02.04.2026 - Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform

Recent Filings

• 03.10.2026 - 8-K Current report
• 02.11.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.21.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 01.13.2026 - 8-K Current report
• 12.30.2025 - EX-99.1 EX-99.1
• 12.30.2025 - 8-K Current report
• 12.19.2025 - 424B5 Prospectus [Rule 424(b)(5)]